Skip to main content
SpringerLink
Log in

Therapie mit Biologika

  • Chapter
Morbus Bechterew

  • 1539 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 62:347–349

    PubMed  Google Scholar 

  • Amor B, Dougados M, Khan MA (1995) Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 21:117–128

    PubMed  Google Scholar 

  • Anderson JJ, Baron G, van der Heijde D, Felson DT, Felson M (2001) ASAS preliminary criteria for short term improvement in ankylosing spondylitis. Arthritis Rheum 44:1878–1886

    Article  Google Scholar 

  • Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 20(Suppl 28):S152–157

    PubMed  Google Scholar 

  • Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47:506–512

    Article  PubMed  Google Scholar 

  • Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT (1996) Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 35:373–376

    PubMed  Google Scholar 

  • Baert F, Noman M, Vermeire S, van Assche G, D’Haens G, Carbonez A, Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348:601–608

    Article  PubMed  Google Scholar 

  • Baeten D, Kruithof E, van den Bosch F, Demeter P, van Damme N, Cuvelier C, de Vos M, Mielants H, Veys E, de Keyser P (2001) Immunmodulatory effects of anti-TNF therapy on synovium in spondyloarthropathy. Arthritis Rheum 44:186–195

    Article  PubMed  Google Scholar 

  • Beutler BA (1999) The role of TNF in health and disease. J Rheumatol 26,S57:16–21

    Google Scholar 

  • Bollow M, Enzweiler C, Taupitz M, Golder W, Hamm B, Sieper J, Braun J (2002) Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. Clin Exp Rheumatol 20(6 Suppl 28):S167–74

    PubMed  Google Scholar 

  • Brandt J, Bollow M, Haberle J, Rudwaleit M, Eggens U, Distler A, Sieper J, Braun J (1999) Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 38:831–836

    Article  PubMed  Google Scholar 

  • Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346–1352

    Article  PubMed  Google Scholar 

  • Brandt J, Haibel H, Reddig J, Sieper J, Braun J (2002a) Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor a monoclonal anti-body infliximab. J Rheumatol 29:118–122

    PubMed  Google Scholar 

  • Brandt J, Haibel H, Sieper J, Reddig J, Braun J (2001) Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 44:2936–2937

    PubMed  Google Scholar 

  • Brandt J, Kariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Sieper J, Braun J (2003) Six months results of a German double-blind placebo controlled clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 48:1667–1675

    Article  PubMed  Google Scholar 

  • Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J (2004) Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 31:531–538

    PubMed  Google Scholar 

  • Brandt J, Listing J, Sieper J, van der Heijde D, Braun J (2002b) Improvement criteria for treatment with biologics of patients with ankylosing spondylitis — a proposal based on data from a recent randomized trial with the anti-TNFa agent infliximab. Arthritis Rheum 46:S380

    Google Scholar 

  • Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, van der Heijde D (2003a) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48:1126–1136

    Article  PubMed  Google Scholar 

  • Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499–505

    PubMed  Google Scholar 

  • Braun J, Bollow M, Sieper J (1998) Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 24:697–735

    PubMed  Google Scholar 

  • Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002a) Treatment of active ankylosing spondylitis with infliximab — a double-blind placebo controlled multicenter trial. Lancet 359:1187–1193

    Article  PubMed  Google Scholar 

  • Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J (2003c) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48:2224–2233

    PubMed  Google Scholar 

  • Braun J, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J (2003d) Biologic therapies in the spondylarthropathies: new opportunities, new challenges. Curr Opin Rheumatol 15:394–407

    Article  PubMed  Google Scholar 

  • Braun J, Breban M, Maksymowych WP (2002b) Therapy for ankylosing spondylitis: new treatment modalities. Best Pract Res Clin Rheumatol 16:631–651

    PubMed  Google Scholar 

  • Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E (2001) New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 13:245–249

    PubMed  Google Scholar 

  • Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D for the ASAS working group (2003b) International ASAS consensus statement for the use of biologic agents in patients with ankylosing spondylitis. Ann Rheum 62:817–824

    Article  PubMed  Google Scholar 

  • Braun J, Sieper J (1996) The sacroiliac joint in the spondylarthropathies. Curr Opin Rheumatol 7:275–283

    Google Scholar 

  • Braun J, Sieper J (2000) Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies? Ann Rheum Dis 59:404–407

    Article  PubMed  Google Scholar 

  • Braun J, Sieper J (2002a) Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res 4:307–321

    PubMed  Google Scholar 

  • Braun J, Sieper J (2002b) (letter) Arthritis Rheum 46:2822–2824

    Article  Google Scholar 

  • Braun J, Sieper J (2003) Role of novel biological therapies in psoriatic arthritis — effects on joints and skin. Biodrugs 17:187–199

    PubMed  Google Scholar 

  • Braun J, Tuszewski M, Ehlers S, Haberle J, Bollow M, Eggens U, Distler A, Sieper J (1997) Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. J Rheumatol 24:1101–1105

    PubMed  Google Scholar 

  • Braun J, van der Heijde D (2002) Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol 16:573–604

    PubMed  Google Scholar 

  • Braun J, Xiang J, Brandt J, Maetzel H, Haibel H, Wu P, Kohler S, Rudwaleit M, Siegert S, Radbruch A, Thiel A, Sieper J (2000) Treatment of spondyloarthropathies with antibodies against tumour necrosis factor a: first clinical and laboratory experiences. Ann Rheum Dis 59(Suppl I):10–14

    Google Scholar 

  • Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, Radbruch A, Sieper J (1999) Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 42:2039–2044

    Article  PubMed  Google Scholar 

  • Breban M, Gombert B, Amor B, Dougados M (1999) Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 42:580–581

    PubMed  Google Scholar 

  • Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, Euller-Ziegler L, Sibilia J, Perdriger A, Mezieres M, Alexandre C, Dougados M (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 41:1280–1285

    Article  PubMed  Google Scholar 

  • Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151–3158

    PubMed  Google Scholar 

  • Calin A, Garrett S, Whitelock HC, Kennedy LG, O’Hea J, Mallorie PA, Jenkinson TR (1994) A new approach to defining functional ability in ankylosing spondylitis. The Bath AS functional index. J Rheumatol 21:2286–2291

    PubMed  Google Scholar 

  • Calin A, Nakache J-P, Gueguen A, Zeidler H, Mielants H, Dougados M (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropiate instrument? Rheumatology 38:878–882

    PubMed  Google Scholar 

  • Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842–1847

    Article  PubMed  Google Scholar 

  • Collantes-Estevez E, Munoz-Villanueva MC, Canete-Crespillo JD et al (2003) Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. Ann Rheum Dis 62:1239–1240

    Article  PubMed  Google Scholar 

  • Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon M, Melton III LJ (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21:1877–1882

    PubMed  Google Scholar 

  • Corral LG, Kaplan G (1999) Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 58,Suppl I:107–113

    Google Scholar 

  • D’Agostino MA, Breban M, Said-Nahal R, Dougados M (2002) Refractory inflammatory heel pain in spondyloarthropathy: a significant response to infliximab documented by ultra-sound. Arthritis Rheum 46:840–841

    Article  PubMed  Google Scholar 

  • D’Agostino MA, Said-Nahal R, Hacquard-Bouder C, Brasseur JL, Dougados M, Breban M (2003) Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: A cross-sectional study. Arthritis Rheum 48:523–533

    Article  PubMed  Google Scholar 

  • Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W and the Enbrel Ankylosing Spondylitis Study Group (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230–3236

    Article  PubMed  Google Scholar 

  • De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A (1989) Ileocolonoscopy in seronegative spondyloarthropathy. Gastroenterology 96:339–344

    PubMed  Google Scholar 

  • D’haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 116:1029–1034

    PubMed  Google Scholar 

  • Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227

    PubMed  Google Scholar 

  • Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B, et al (1995) Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38: 618–627

    PubMed  Google Scholar 

  • Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al (1994a) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105–1110

    Article  PubMed  Google Scholar 

  • Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994b) Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125–1127

    Article  PubMed  Google Scholar 

  • El-Shabrawi Y, Hermann J (2002) Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109:2342–2346

    Article  PubMed  Google Scholar 

  • Feldmann M (1996) What is the mechanism of action of anti-tumour necrosis factor-alpha anti-body in rheumatoid arthritis? Int Arch Allergy Immunol 111:362–365

    PubMed  Google Scholar 

  • Ferraz MB, Tugwell P, Goldsmith CH, Atra E (1990) Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17:1482–1486

    PubMed  Google Scholar 

  • Furst DE, Breedveld FC, Kalden JR, Smolen JS (1999) Building towards a consensus for the use of tumour necrosis factor blocking agents. Ann Rheum Dis 58:725–726

    PubMed  Google Scholar 

  • Gaylis N (2003) Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. J Rheumatol 30:407–411

    PubMed  Google Scholar 

  • Gorman JD, Sack KE, Davis JC (2000) Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 43:S403

    Article  Google Scholar 

  • Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 36:766–771

    Article  PubMed  Google Scholar 

  • Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett S, Calin A (1994) Defining spinal mobility in ankylosing spondylitis. The Bath AS metrology index. J Rheumatol 21:1694–1698

    PubMed  Google Scholar 

  • Kavanaugh AF (1998) Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 24:593–614

    PubMed  Google Scholar 

  • Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P (2000) Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. JRheumatol 27:841–850

    Google Scholar 

  • Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104

    Article  PubMed  Google Scholar 

  • Kempeni J (1999) Preliminary results of early clinical trials with the fully human anti-TNF alpha monoclonal antibody D2E7. Ann Rheum Dis 58,Suppl I:170–172

    Google Scholar 

  • Leirisalo-Repo M (1998) Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am 24:737–751

    PubMed  Google Scholar 

  • Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014–2022

    Article  PubMed  Google Scholar 

  • MacKay K, Mack C, Brophy S, Calin A (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new validated approach to disease assessment. Arthritis Rheum 41:2263–2270

    PubMed  Google Scholar 

  • Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563

    Article  PubMed  Google Scholar 

  • Maini R et al. ATTRACT Study Group (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932–1939

    PubMed  Google Scholar 

  • Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, Luongo R, Russell AS (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29:959–965

    PubMed  Google Scholar 

  • Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yan A, Russell AS (1998) An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 25:714–717

    PubMed  Google Scholar 

  • Marzo-Ortega H, McGonagle D, O’Connor P, Emery P (2001) Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 44:2112–2117

    Article  PubMed  Google Scholar 

  • Marzo-Ortega H, McGonagle D, O’Connor P, Emery P (2003) Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 62:74–76

    Article  PubMed  Google Scholar 

  • Meador R, Hsia E, Kitumnuaypong T, Schumacher HR (2002) TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin Exp Rheumatol 20(6 Suppl 28):S130–134

    PubMed  Google Scholar 

  • Mease P (2002) Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61:298–304

    Article  PubMed  Google Scholar 

  • Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385–390

    PubMed  Google Scholar 

  • Mielants H, Veys EM, Cuvelier C, De Vos M (1996) Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 10:147–164

    PubMed  Google Scholar 

  • Moreland LW (1999) Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 26,Suppl 57:7–15

    PubMed  Google Scholar 

  • Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478–486.

    PubMed  Google Scholar 

  • Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U (1988) Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 31:1111–1116

    PubMed  Google Scholar 

  • Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Lueftl M (2001) Treatment of psoriatic arthritis with antitumour necrosis factor α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144:587–589

    Article  PubMed  Google Scholar 

  • Oili KS, Niinisalo H, Korpilahde T, Virolainen J (2003) Treatment of reactive arthritis with infliximab. Scand J Rheumatol. 32:122–124

    Article  PubMed  Google Scholar 

  • Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F (2002) Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 61:375–376

    Article  PubMed  Google Scholar 

  • Pennanen N, Lapinjoki S, Urtti A, Monkkonen J (1995) Effect of liposomal and free bisphos-phonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 12:916–922

    Article  PubMed  Google Scholar 

  • Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    PubMed  Google Scholar 

  • Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44:1977–1983

    Article  PubMed  Google Scholar 

  • Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, Sieper J, Braun J (2000) Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA B27 and influence of the TNF-308 gene polymorphisms. Ann Rheum Dis 60:36–42

    Article  Google Scholar 

  • Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761–769

    PubMed  Google Scholar 

  • Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R (2003) Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 17:185–192

    Article  PubMed  Google Scholar 

  • Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088–1094

    PubMed  Google Scholar 

  • Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK (2001) Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7:83–88

    Article  PubMed  Google Scholar 

  • Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45:252–257

    Article  PubMed  Google Scholar 

  • Spoorenberg A, de Vlam K, van der Heijde D, de Klerk E, Dougados M, Mielants H, et al. (1999) Radiologic scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol 26:997–1002

    PubMed  Google Scholar 

  • Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R (2001) Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 28:1605–1614

    PubMed  Google Scholar 

  • Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR (2002) Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 97:2577–2584

    Article  PubMed  Google Scholar 

  • Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ, Crohn’s Disease cA2 Study Group (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med 337:1029–1035

    Article  PubMed  Google Scholar 

  • Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, Drosos AA (2003) Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 62:1218–1220

    Article  PubMed  Google Scholar 

  • Torre-Amione G, Vooletich MT, Farmer JA (2000) Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs 59:745–751

    PubMed  Google Scholar 

  • van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000b) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59:428–433

    Article  PubMed  Google Scholar 

  • van den Bosch F, Kruithof E, Baeten D, Herseens A, De Keyser F, Mielants H, Veys EM (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 46:755–765

    Article  PubMed  Google Scholar 

  • van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H (2000a) Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356:1821–1822

    Google Scholar 

  • van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24:2225–2229

    PubMed  Google Scholar 

  • Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H (2002) Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46:1965–1968

    Article  PubMed  Google Scholar 

  • Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 28:253–259

    Article  Google Scholar 

  • Zink A, Braun J, Listing A, Wollenhaupt J, and the German Colloborative Research Centers (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis — results of the German rheumatological database. J Rheumatol 27:613–622

    PubMed  Google Scholar 

  • Zou JX, Braun J, Sieper J (2002) Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol. 20(6 Suppl 28):S34–37

    PubMed  Google Scholar 

  • Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J (2003a) Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 62:561–564

    Article  PubMed  Google Scholar 

  • Zou J, Zhang Y, Thiel A, Rudwaleit M, Shi SL, Radbruch A, Poole R, Braun J, Sieper J (2003b) Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) 42:846–855

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Jürgen Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sonderkrankenanstalt — Rehabilitationszentrum Bad Ischl-Lindau Pensionsversicherungsanstalt, Bad Ischl, Österreich

    Albrecht Felkenbach

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag/Wien

About this chapter

Cite this chapter

Braun, J. (2005). Therapie mit Biologika. In: Felkenbach, A. (eds) Morbus Bechterew. Springer, Vienna. https://doi.org/10.1007/3-211-26646-1_26

Download citation

  • DOI: https://doi.org/10.1007/3-211-26646-1_26

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-00808-9

  • Online ISBN: 978-3-211-26646-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation